Avillion/AstraZeneca’s Budesonide/Albuterol Combo For Asthma Has ‘Uncertain’ Pediatric Benefit

US FDA is asking an advisory committee whether extrapolation of adult data is appropriate to bridge uncertainties in efficacy for asthma patients under age 18 years; metered-dose inhaler would be the first combination product approved in the US containing an inhaled corticosteroid and a short-acting beta2-adrenergic agonist.

Foot bridge
FDA asks whether extrapolation of adult data is appropriate as a bridge to efficacy in the pediatric population. • Source: Shutterstock

The US Food and Drug Administration is asking its external advisors to weigh the uncertainty of pediatric efficacy data for Avillion LLP’s novel, fixed-dose combination of budesonide and albuterol sulfate for asthma.

Efficacy of the budesonide/albuterol (BDA) combination (also known as PT027) was demonstrated in the overall population of the Phase III...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers